Boehringer Ingelheim discontinued development of an inhaled gene therapy for cystic fibrosis that had entered early‑stage clinical testing, the company told Endpoints News. The sponsor decided to terminate the study and wind down the program. The stop highlights risks and scientific challenges in non‑viral or inhaled gene delivery for airway disease, a field that has seen mixed clinical traction despite high unmet need. For investors and translational teams, the move underscores the importance of delivery platform robustness and durable expression in pulmonary gene‑therapy programs. Affected clinical sites and patients will receive company communications on study closure and follow‑up; Boehringer did not disclose detailed scientific reasons publicly at the time of the report.